Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-237P is a segment of genomic DNA classified as a pseudogene, originating from the U6 small nuclear RNA gene family. U6 snRNA itself is a highly conserved non-coding RNA, central to the spliceosome's catalytic activity in pre-mRNA splicing in eukaryotes[1][3]. The “237” in the name refers to its specific locus or copy number in the human genome. Pseudogenes like RNU6-237P generally arise from gene duplication or retrotransposition and lack conservative function due to mutations or absence of regulatory elements. While some non-coding RNA pseudogenes may be transcribed in cancer or other disease states, no disease association or therapeutic application has been described for RNU6-237P specifically[4]. Copies of U6 pseudogenes are common in vertebrate genomes, reflecting the evolutionary importance and high conservation of the parent U6 snRNA gene[3].
Not applicable for pseudogenes
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 237, pseudogene (RNU6-237P).